Sales of Boehringer In­gel­heim's di­a­betes, pul­monary drugs jump with­in $11B+ first-half to­tal

Boehringer In­gel­heim’s phar­ma di­vi­sion sales led com­pa­ny earn­ings for the first half of 2022, notch­ing a sales in­crease of al­most 12%. Its phar­ma busi­ness ac­count­ed for €8.4 bil­lion of its over­all €11.2 bil­lion first-half sales, the phar­ma com­pa­ny re­port­ed on Wednes­day.

Lead­ing the way in phar­ma sales were the di­a­betes brand Jar­diance at €2.5 bil­lion and id­io­path­ic pul­monary fi­bro­sis drug Ofev at €1.5 bil­lion in the first half. Jar­diance’s sales jumped by more than 74% com­pared to the first half of 2021 sales of €1.4 bil­lion. Full-year 2021 Jar­diance sales were €3.9 bil­lion, while Ofev earned €2.5 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER